Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13985956 | 0.88 | HSD11B1 (0.46) | HSD11B1APP | |
| SCHEMBL13635043 | 0.86 | HSD11B1 (0.44) | HSD11B1APPSCN2ASCN10A | |
| SCHEMBL4378539 | 0.86 | HSD11B1 (0.68) | HSD11B1APP | |
| SCHEMBL4378568 | 0.77 | ALDH1A1 (0.43) | HSD11B1KDM4EGAA | |
| SCHEMBL4384504 | 0.74 | RORA (0.52) | KDM4E | |
| SCHEMBL12645426 | 0.74 | HSD11B1 (0.51) | HSD11B1APPKDM4EGAARAB9A | |
| SCHEMBL6027028 | 0.74 | APP (0.44) | HSD11B1APPKDM4EGAARAB9A | |
| SCHEMBL5899840 | 0.68 | RAB9A (0.70) | KDM4EGAARAB9A | |
| SCHEMBL19248162 | 0.66 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL8343599 | 0.66 | GAA (0.51) | KDM4EGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893609-B1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7462634-B2 | N-(pyridin-2-yl)-sulfonamide derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| EP-1893609-A1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070072914-A1 | N-(pyridin-2-yl)-sulfonamide derivatives | AGOURON PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006134467-A1 | N-(PYRIDIN-2-YL)-SULFONAMIDE DERIVATIVES | PFIZER INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072914-A1 | N-(pyridin-2-yl)-sulfonamide derivatives | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885APP 2328/4885SCN2A 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.